How drug repurposing could speed up cancer breakthroughs

Drug discovery is a lengthy process, often taking over a decade and billions of dollars to bring a new compound from the lab to a patient. However, the majority of candidates fail early on due to unforeseen toxicity or lack of efficacy. This is particularly problematic for patients with aggressive, treatment-resistant cancers like triple-negative breast cancer, who cannot afford to wait.

This is where drug repurposing comes in as a promising approach. The concept is straightforward: utilize medications that are already approved for other uses, such as metabolic conditions, inflammation, or viral infections, to determine if they also work against cancer. Since these drugs have already undergone safety testing, dosing studies, and years of real-world use, a significant amount of guesswork is already completed.

Existing drugs like metformin, a type 2 diabetes medication, and aspirin have shown potential in inhibiting tumor growth and improving survival rates. Drug repurposing is not just about directly killing cancer cells; it also involves helping the immune system recognize the tumors. Some non-cancer drugs interfere with the immune-suppressing environment that tumors create, thus turning "cold" tumors "hot" and more susceptible to immune therapy.

This approach is particularly relevant in Qatar, which has invested in robust biomedical infrastructure over the past decade. With locally established precision medicine tools and population-level data from the Qatar Genome Programme, researchers in Qatar can specifically tailor repurposed candidates to the region's unique genetic variants and disease patterns.

This offers a faster pathway into local clinical trials, complementing the slower discovery of entirely new drugs. Drug repurposing is not a replacement for early-stage drug discovery but a complementary approach that can provide patients with options sooner, without compromising on the longer-term scientific advancements.